Research programme: Epstein-Barr virus therapy - MacroGenics
Latest Information Update: 24 Apr 2007
At a glance
- Originator EBVax; Tufts University
- Developer EBVax; MacroGenics; Tufts University
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Epstein-Barr virus infections
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Epstein-Barr virus infections in USA (unspecified route)
- 30 May 2002 Preclinical trials in Epstein-Barr virus infections in USA (unspecified route)